Scancell confirms advanced talks on takeover of Neuphoria; eyes Nasdaq
(Alliance News) - Scancell Holdings PLC on Friday confirmed it was in advanced talks to acquire Neuphoria Therapeutics Inc, which could facilitate a Nasdaq listing.
Scancell, an Oxford-based pharmaceutical company focused on cancer immunotherapies, said the talks are regarding a potential reverse merger transaction, whereby it would buy Nasdaq-listed biotechnology firm Neuphoria via an all-share transaction.
The acquisition could increase Scancell's profile with US specialist investors, the firm said.
Scancell added: "Concurrently, Scancell is in discussions regarding possible equity and debt financing to support a planned global phase 3 registrational study for its lead asset, iSCIB1+."
Sancell explained: "iSCIB1+, the lead product from their DNA ImmunoBody platform has demonstrated safe, durable and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in a phase 2 trial in melanoma."
The company does not expect that the potential transaction would constitute a reverse takeover under London AIM market rules.
It added that there can be no certainty that a firm agreement with Neuphoria will be reacted.
Scancell shares fell 4.0% to 18.25 pence each on Friday afternoon in London, while Neuphoria shares opened 2.1% lower at USD4.27 each in New York.
By Tom Budszus, Alliance News slot editor
Comments and questions to newsroom@alliancenews.com
Copyright 2026 Alliance News Ltd. All Rights Reserved.
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
More In Markets
Bank of Japan Outlook: Rate Hike Likely to Support Yen
How AI Is Taking Over Your Portfolio
